Kornimate/medical-research-clean huggingface dataset:
influenze of approach in reversed shoulder prosthesis

Conditions: Outcomes Assessments, Patients; Rotator Cuff Arthropathy

Summary: to determine the differences in the placement of the glenoid implant of the inverted prostheses when they are implanted using a superior approach and using an anterior approach.

inverted prostheses have proven to be effective in the treatment of all those pathologies that involve a deterioration of the rotator cuff (secondary arthropathy, acute fractures, sequelae of fractures, tumor surgery and revision surgery). despite this, numerous complications have been described after the use of inverted prostheses, such as glenoid erosion, infections, dislocation, or aseptic loosening. the most frequent complication related to the use of inverted prostheses is glenoid erosion that can occur in up to 96% of cases. this complication appears early in the evolution, usually before 2 years after surgery. its clinical significance is not yet clear, but it seems that it may be a cause of long-term prosthetic loosening. to avoid the development of glenoid erosion, the best option is to place the glenoid component low, so that if the glenoid component is flush with the lower margin of the glena, the chances of developing glenoid erosion are significantly reduced. two types of approaches have been used to implant these prostheses, the deltopectoral and the superior anterior approach. each of them has its advantages and disadvantages, so that deltopectoral seems to improve surgical exposure and therefore favors the best placement of the glenoid component, but sacrifices the subscapularis tendon, increasing the risk of dislocation of the components. on the contrary, the superior anterior approach respects the subscapularis tendon, reducing the risk of dislocation of the components but gives worse surgical exposure.

Eligibility criteria:
inclusion criteria: * patients with secondary osteoarthritis of the shoulder who are candidates for an inverted prosthesis * acute fractures \<2 weeks of evolution in patients candidates for inverted prostheses * no previous surgeries of the affected shoulder * acceptance by the patient to participate in the study exclusion criteria: * fractures\> 2 weeks of evolution * previous surgeries on the affected shoulder * not signing the informed consent * cognitive impairment * institutionalization of the patient

Keywords: reverse shoulder arthroplasty scapular notch deltopectoral anterosuperior approach
studying genes for barrett's esophagus in brothers and sisters

Conditions: Esophageal Cancer; Precancerous Condition

Summary: rationale: learning about how often heartburn and other risk factors occur in brothers and sisters and other family members of patients with barrett's esophagus may help identify other individuals at risk and identify genes for barrett's esophagus. purpose: this clinical trial is studying genes for barrett's esophagus in brothers and sisters.

objectives: primary * to investigate the familial incidence of heartburn and barrett's esophagus in first and second degree relatives of patients with barrett's esophagus in the united kingdom. * to determine susceptibility genes for barrett's esophagus in affected sibling pairs. * to examine gene-environment interactions, such as smoking, alcohol, and helicobacter pylori status, on familial susceptibility to heartburn and barrett's esophagus. secondary * to compare the mortality from esophageal adenocarcinoma in family members with heartburn and barrett's esophagus with deaths from other causes. outline: this is a multicenter study. patients complete a family history questionnaire. epidemiological data is also collected about environmental exposures, such as smoking and alcohol history. any siblings or other living family members affected by heartburn identified from this survey are then contacted to validate their symptoms/diagnoses and to collect other relevant epidemiological data. family members with heartburn are offered a screening endoscopy for the presence of barrett's esophagus. in the absence of an endoscopy, a symptom nomogram predictive for the presence of barrett's esophagus is used. patients and their siblings, as well as any other willing family member (affected or non-affected) are asked to have a blood sample (edta tube for genetic analysis and a serum sample for helicobacter pylori status) taken by their physician. genomic dna is extracted from lymphocytes and a genome-wide scan is performed using a standard marker set. a computer program is used to verify sibling relationships. individuals not found to be full siblings are excluded from subsequent analyses. maximum likelihood score (mls) and the nonparametric linkage score (npl) is used to estimate the degree of linkage. all study participants are flagged with the national health service (nhs) central register to ascertain the future mortality from esophageal adenocarcinoma compared with deaths from other causes. projected accrual: a total of 200 sibling pairs will be accrued for this study.

Eligibility criteria:
disease characteristics: * sibling pairs will be recruited either from the united kingdom national barrett's oesophagus registry (ukbor) of patients with barrett's esophagus from 37 centers or from national health service hospitals patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: adenocarcinoma of the esophagus esophageal cancer barrett esophagus
a study to evaluate the efficacy of teprenone on chinese patients with chronic non-atrophic erosive gastritis

Conditions: Chronic Erosive Gastritis

Summary: the purpose of this study is to evaluate the efficacy of teprenone on chronic non-atrophic erosive gastritis and its therapeutic mechanism


Eligibility criteria:
inclusion criteria: 1. 18-65 years old 2. have been diagnosed as chronic non-atrophic erosive gastritis by endoscopy within 1 weeks before enrollment, and the modified lanza score ≥ 2 3. have at least two symptoms in four major symptoms (epigastric pain, epigastric burning, early satiety, belching) and total symptom score ≥ 4 (rome ⅲ for functional gastrointestinal disorders) exclusion criteria: 1. suspected upper gastrointestinal malignancy by endoscopy 2. peptic ulcer and bleeding by endoscopy 3. severe cardiac, hepatic or renal insufficiency 4. severe neurological or psychological disease 5. pregnant or lactating women 6. have taken drugs which may affect evaluating the efficacy of study drug within two weeks before enrollment (includes but not limits to: proton pump inhibitors such as omeprazole, rabeprazole, pantoprazole, lansoprazole, esomeprazole, h2 receptor antagonists such as cimetidine, ranitidine, famotidine, antacids such as calcium carbonate, gastric mucosal protectants such as colloidal bismuth potassium citrate and other bismuth products, sucralfate, aluminum phosphate, teprenone, gefarnate, aluminum magnesium carbonate, glutamine, rebamipide, ecabet, misoprostol, antibiotics such as amoxicillin, clarithromycin, tetracycline, ofloxacin, levofloxacin, furazolidone, metronidazole, tinidazole, non-steroid anti-inflammatory drugs such as aspirin, ibuprofen, loxoprofen, naproxen, diclofenac, indomethacin, meloxicam, acetaminophen) 7. history of allergic reaction to the medications used in this study 8. patients that investigators consider ineligible for this study

Keywords: chronic erosive gastritis teprenone sucralfate
mindfulness and lifestyle interventions for depression and anxiety: a pilot study

Conditions: Depression; Anxiety; Major Depression

Summary: this is a quasi-experimental evaluation of psychoeducational course focusing on mindfulness and lifestyle changes for depression and anxiety; clients in active treatment group are compared to those in a treatment-as-usual wait-list control group. the primary hypothesis is that the psychoeducational course will result in lower levels of depression and anxiety as compared to the wait-listed treatment-as-usual comparison group.

this study evaluates a psychoeducational intervention: teaching mindfulness and lifestyle interventions to adult clients who self-report problems with depression and/or anxiety. the course is eight weeks long. clients are assigned to either (1) receive the course (cou condition) from october- december 2010 or (2) placed on a waiting list and receive treatment-as-usual (tau condition). those in the tau group will be offered the course in january 2011. random assignment to cou or tau conditions will be attempted although this may be relaxed due to institutional constraints. participants are assessed on the beck depression inventory (bdi) and beck anxiety inventory (bai) at the beginning of the course, on the last day of the course, at 1-month post-course, at 4-months post-course, and at 12-months post-course. participants in the cou condition will be compared to those in tau condition at the beginning of the course, on the last day of the course, and at 1-month post-course. further evaluations (4 and 12 months post-course) will be pre-post evaluations without a comparison group.

Eligibility criteria:
inclusion criteria: * participants self-report as having depression or anxiety * adults (age 18 or above) * clients willing to participate in an 8-week psychoeducational course exclusion criteria: * a diagnosis of a psychotic disorder * unwilling to participate in 8-week psychoeducational course

Keywords: depression anxiety psychoeducation self-help psychosocial
airway ultrasound prediction and correlation

Conditions: Obstructive Sleep Apnea; Difficult Airway

Summary: this is a novel approach to assess the use of ultrasound to support the identification of obstructive sleep apnea syndrome (osas) on a screening questionnaire, and potentially to predict a difficult pediatric airway. the investigators hope to determine if a combination of simple bedside clinical tests can be used to identify osas in patients who present for surgery with clinical signs of osas but without a formal polysomnography.


Eligibility criteria:
inclusion criteria: * all children presenting for surgery at nch ranging in age from 3-12 years exclusion criteria: * parent/ patient refusal to participate in study
diagnostic dna methylation signature in diagnosing thyroid cancer after fine-needle aspiration in patients with thyroid nodules

Conditions: Thyroid Gland Nodule

Summary: this trial studies how well the diagnostic deoxyribonucleic acid (dna) methylation signature works in detecting thyroid cancer in patients with thyroid nodules. using diagnostic testing, such as the diagnostic dna methylation signature, may be a less invasive way to check for thyroid cancer.

primary objectives: i. to validate a novel epigenetic thyroid nodule diagnostic test, diagnostic dna methylation signature (ddms) in a retrospective-prospective study with leftover of fine needle aspiration biopsies. outline: previously collected fna aspiration specimen samples are analyzed via ddms assay. participants undergo fna aspiration for collection of tissue samples for analysis via ddms assay. after completion of study, patients are followed up yearly for 5 years.

Eligibility criteria:
inclusion criteria: * all patients undergoing fna for thyroid nodule diagnosis. * any race and ethnicity are eligible for the study. * patient should have thyroid nodule(s) with indeterminate diagnosis after fna (bethesda category of indeterminate fna \[iii-v\]).
trial of aeroquin versus tobramycin inhalation solution (tis) in cystic fibrosis (cf) patients

Conditions: Cystic Fibrosis

Summary: patients with cystic fibrosis (cf) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in cf patients. aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat cf patients with pulmonary infections caused by multi-drug resistant pseudomonas aeruginosa and other bacteria. high concentrations of mp-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms.

this study will assess the comparative safety of mp-376 (aeroquin) and tobramycin inhalation solution (tis) \[tobi® novartis pharmaceuticals\] over three consecutive cycles of 28-days treatment followed by 28-days off in stable cf patients with chronic p. aeruginosa lung infection. efficacy data for mp-376 and tis at the end of the first 28-day treatment period will also be compared, as well as explored over multiple treatment cycles. study patients participating in mpex 209 will be given the option to participate in a six-month open label extension phase of the mpex 209 protocol. the open label extension will allow enrolled patients to receive three additional courses of mp-376 (levofloxacin inhalation solution, aeroquin™). study with completed results acquired from horizon in 2024.

Eligibility criteria:
inclusion criteria (selected): * \> 12 years of age * confirmed diagnosis of cystic fibrosis * positive sputum culture for p. aeruginosa within the past 12 months * patients are able to elicit an fev1 \>/= 25% but \</= 85% of predicted value at screening * have received at least 3 courses of inhaled tobramycin over the preceding 12 months * clinically stable with no changes in health status within the last 28 days * able to reproducibly produce sputum and perform spirometry exclusion criteria (selected): * use of any nebulized or systemic antibiotics within 28 days prior to baseline * history of hypersensitivity to fluoroquinolones or inhaled or systemic aminoglycosides including tobramycin or any excipients * evidence of acute upper within 10 days or lower respiratory infections within 28 days prior to dosing * crcl \< 20 at screening * history of lung transplantation extension portion of the study: patients enrolled in mpex 209 are permitted to participate in the open label extension as long as they complete visit 7 (day 168), provide informed consent for participation in the open label extension of in the study and are clinically stable, as assessed by the investigator.
providing patients realistic expectations of postoperative pain

Conditions: Pain, Postoperative

Summary: prospective, randomized, single-blind study, whether perioperative educational improves pain-related postoperative outcomes,

this is a prospective, randomized, single-blind study in 100 patients undergoing open colorectal surgery. if the hypothesis is confirmed, then patients who receive perioperative educational interventions to address their expectation about their postoperative pain will have improved pain-related postoperative outcomes. randomization and blinding 100 eligible patients scheduled to undergo open colorectal surgery will be approached in the center for preoperative assessment and planning clinic. at enrollment, each patient will be assigned a study number, which will match a previously prepared computer-generated list of randomization numbers to determine whether they will be in the intervention or control arm. pre-operatively, all patients will complete an initial questionnaire. the patients in the intervention group (n=50) will, in addition to the standard pre-operative assessment, also receive pre-operative educational instruction of what to expect from a post-operative pain perspective including education material to take home. for this study, deception will be used, with the reasoning that the patients' knowledge of the different education materials will affect their rating of the impact of the intervention on satisfaction scores.

Eligibility criteria:
inclusion criteria: * age \> 18 years * undergoing open colorectal surgery able to understand and sign and informed consent form exclusion criteria: * age \< 18 years * unable to complete post-operative cms questionnaire * inability to understand the english language absolute contraindication to epidural placement (patient refusal, requiring resumption of therapeutic anticoagulation after surgery, anaphylaxis to local anesthetics, local or systemic infections, bleeding diathesis)
radiotherapy combined with thymosin for metastatic nsclc patients who showed stable disease after first line tki therapy

Conditions: Lung Adenocarcinoma

Summary: the investigators postulated that the exploitation of the pro-immunogenic effects of radiotherapy with thymosin might result in abscopal responses among patients with metastatic cancer. the research is designed to evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy combined with thymosin alpha 1. an exploratory biomarker analysis in blood and tumor samples is also planned.


Eligibility criteria:
inclusion criteria: * newly diagnosed metastatic lung adenocarcinoma harboring sensitizing egfr mutations (l858r, exon 19 deletion), and showed stable disease after 3 months tki, evaluated twice by pet/ct scan, brain mri, and abdomen ultrasound (≥3 measurable lesions, and these lesions haven't received local therapy) * age 18 years or older * ecog performance status 0-2 * adequate bone marrow, liver and renal function, as specified below: absolute neutrophil count (anc) ≥ 1.5 x 109/l; hemoglobin ≥ 8 g/dl; platelets ≥ 100 x 109/l; serum total bilirubin ≤ 1.5 x upper limit of normal (uln) ; ast and alt ≤ 2.5 x uln or ≤ 5 x uln if liver metastases are present; serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal * for women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment * men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter * patients and their family signed the informed consents exclusion criteria: * received chemotherapy before tki therapy * brain parenchyma or leptomeningeal disease * concurrent malignancies other than non-melanoma skin cancer that require active ongoing treatment * any medical co-morbidities that would preclude radiation therapy.

Keywords: hypofractionated radiotherapy thymosin alpha 1 lung adenocarcinoma tyrosine kinase inhibitors
cerebrovascular events in patients undergoing transcatheter aortic valve implantation with balloon-expandable valves versus self-expandable valves.

Conditions: Aortic Valve Stenosis

Summary: the aim of this collaborative analysis is to evaluate stroke rates and mortality in patients undergoing tavi with the self-expandable mcv prosthesis compared to the balloon-expandable es valve. in the absence of large randomized controlled trials, we will conduct a large collaborative patient-pooled meta-analysis on 30-day stroke and mortality in patients undergoing primary transfemoral tavi with either mcv or es valve.

the main aim of this patient-pooled analyses is to compare stroke rates and mortality in patients undergoing tavi with the self-expandable mcv prosthesis compared to the balloon-expandable es valve. however, this collaboration may also be used to compare various outcomes. studies were included if they complied with the following requirements: original prospective studies, including patients with aortic valve stenosis treated with transfemoral tavi of native valves and reporting of 30 day stroke outcomes according to varc criteria or other specified corresponding criteria . moreover, to be included studies had to report both the use of self-expandable mcv prosthesis and the balloon-expandable es valve in more than 50 patients in each arm to ensure experience in use of the valves. studies were excluded if they only addressed patients undergoing valve-in-valve and re-do procedures or bicuspid valves or included the same study population. principal investigators of these studies were approached for collaboration.

Eligibility criteria:
inclusion criteria: * patients undergoing transfemoral transcatheter aortic valve procedures exclusion criteria: * valve-in-valve procedures, other acces routes than transfemoral
a study of tislelizumab in combination with chemotherapy versus chemotherapy in advanced lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: an open-label, randomized, multicenter phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (nsclc).


Eligibility criteria:
key inclusion criteria: 1. age 18-75 years old, male or female, and signed informed consent form (icf) 2. advanced nsclc diagnosed by pathological or clinical physicians 3. eastern cooperative oncology group (ecog) performance status (ps) ≤ 1 4. participants must have ≥ 1 measurable lesion as defined per response evaluation criteria in solid tumors (recist) v1.1 5. must be treatment-naive for locally advanced or metastatic squamous nsclc 6. life expectancy ≥ 12 weeks 7. participants must have adequate organ function 8. male/female is willing to use a highly effective method of birth control key exclusion criteria: 1. diagnosed with nsclc but with epidermal growth factor receptors (egfr)-sensitizing mutation or anaplastic lymphoma kinase (alk) gene translocation 2. received any approved systemic anticancer therapy 3. received prior treatment with egfr inhibitors or alk inhibitors 4. received prior therapies targeting programmed death 1 (pd-1) or programmed death ligand 1 (pd-l1) 5. with history of interstitial lung disease 6. clinically significant pericardial effusion 7. severe infections, active leptomeningeal disease or uncontrolled, untreated brain metastasis 8. any major surgical procedure before randomization 9. human immunodeficiency virus infection 10. untreated hepatitis b virus (hbv)/hepatitis c virus (hcv) 11. active autoimmune diseases or history of autoimmune diseases 12. history of allergic reactions to chemotherapy note: other protocol defined inclusion/exclusion criteria may apply.